Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00005044 · FLOW

Participant flow

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer · Source last updated 2022-06-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
    id
    FG000
    title
    TAS x 8 Weeks
  2. description
    TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
    id
    FG001
    title
    TAS x 28 Weeks
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        37
      2. group Id
        FG001
        num Subjects
        46
      type
      Protocol Violation
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      No protocol treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        790
      2. group Id
        FG001
        num Subjects
        789
      type
      STARTED
    2. achievements
      1. comment
        Subjects with data available for the primary analysis are considered to have completed the study.
        group Id
        FG000
        num Subjects
        752
      2. comment
        Subjects with data available for the primary analysis are considered to have completed the study.
        group Id
        FG001
        num Subjects
        737
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        38
      2. group Id
        FG001
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
    id
    FG000
    title
    TAS x 8 Weeks
  2. description
    TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
    id
    FG001
    title
    TAS x 28 Weeks
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        37
      2. group Id
        FG001
        num Subjects
        46
      type
      Protocol Violation
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      No protocol treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        790
      2. group Id
        FG001
        num Subjects
        789
      type
      STARTED
    2. achievements
      1. comment
        Subjects with data available for the primary analysis are considered to have completed the study.
        group Id
        FG000
        num Subjects
        752
      2. comment
        Subjects with data available for the primary analysis are considered to have completed the study.
        group Id
        FG001
        num Subjects
        737
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        38
      2. group Id
        FG001
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice